Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 17 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Gloo Holdings, Inc. (NASDAQ: GLOO) Prices $72.8 Million IPO
Gloo (NASDAQ: GLOO) , a technology platform serving the faith and flourishing ecosystem, priced its…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Positioned for Growth as War Department Launches Billion-Dollar Push for U.S. Drone Dominance
Safe Pro Group (NASDAQ: SPAI), a mission-driven provider of AI-powered defense and security solutions, is…
-
QualityStocksNewsBreaks – Decent Holding Inc. (NASDAQ: DXST) Closes $8 Million Registered Offering of Class A Shares and Warrants
Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8…